RHOA at the intersection of inflammation-driven and sporadic colorectal cancer

Category	Detail
Condition	Colorectal Cancer (CRC)
Key Mechanisms	RHOA regulates cytoskeleton dynamics and is involved in oncogenic pathways related to CRC and colitis-associated cancer (CAC).
Target Population	Patients with colorectal cancer, particularly those under 50 and those with inflammatory bowel diseases (IBDs).
Care Setting	Oncology and gastroenterology clinics.

Colorectal cancer accounts for approximately 10% of all malignant tumors and is the second leading cause of cancer-related death.
Colitis-associated cancer (CAC) arises from chronic inflammation and has a worse prognosis compared to sporadic CRC.
RHOA's role in cancer is controversial, acting as both a tumor promoter and suppressor depending on context.
Distinct genetic features exist between sporadic CRC and CAC, with implications for treatment and prognosis.
Therapeutic targeting of RHOA and related proteins may offer new opportunities for CRC management.

Clinical symptoms of CRC include changes in bowel habits, rectal bleeding, abdominal pain, weight loss, fatigue, iron deficiency, and anemia.

Consider molecular subtyping for patient stratification and treatment interventions.

Monitor for specific genetic mutations associated with CRC and CAC for tailored therapeutic approaches.

Increased risk of CRC in patients with inflammatory bowel diseases compared to the general population.

Patients diagnosed with colorectal cancer, particularly those with inflammatory bowel diseases.

Understanding RHOA's function may help identify limitations in developing novel therapeutic targets.

Utilize whole-exome sequencing to identify genetic alterations in CRC and CAC.
Focus on the inflammatory context when assessing RHOA's role in tumor development.

Clinical Scorecard: RHOA's Role in Inflammation-Related and Sporadic Colorectal Cancer